Navigation Links
Sidec Announces the First Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS
Date:5/1/2008

BOSTON, Massachusetts, May 1 /PRNewswire/ -- Sidec announces the first Protein Tomography(TM) Award at Sidec's Executive Forum at PEGS. This Award is set up to enable research groups in the biopharmaceutical industry, who have not yet collaborated with Sidec on a Protein Tomography(TM) study, to get acquainted with Sidec's groundbreaking technology successfully used in cancer drug research.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

Sidec announced today the first Protein Tomography(TM) Award. The winning project will obtain a Protein Tomography(TM) collaboration financed by Sidec. This announcement was made at Sidec's Executive Forum during the fourth Annual PEGS meeting organized by CHI.

The use of Protein Tomography(TM) to answer questions related to therapeutic antibody development was presented at Sidec's Executive Forum. Berkley Lynch, previously Principal Investigator at UCB, spoke about the use of Protein Tomography(TM) to Image the Synaptic Vesicle of protein 2A in situ and Jose R. Casas-Finet, Director, R&D and Medical Biochemistry, MedImmune showed how antibody conformations and interactions can be studied by Protein Tomography(TM). At the Forum, Wim, K. Bleeker, Director Translational Research & Pharmacology at Genmab presented the modes of action of HuMax-EGFr (zalutumumab) published in PNAS April 22nd and how this was determined together with Sidec using Protein Tomography(TM).

Finally, Kathleen Madden Williams, PhD, JD Edwards Agnell Palmer & Dodge LLP discussed the ever-narrowing tunnel that present day patent protection on antibodies has entered and whether there is a gold standard by which antibodies are distinguishable from one another thereby to enable more meaningful patent protection.

"During PEGS it became obvious that studying molecular mechanisms is indeed a crucial step in antibody development. Even for some of the best studied anti cancer drug targets, such as CD20, a fundamental understanding of the drug mechanisms is still lacking. Hence, Sidec's Protein Tomography(TM) Award fills an important role in encouraging research groups in the biopharmaceutical industry to try a new avenue, such as Protein Tomography(TM), to increase their chances of success" says Hans Johansson CEO at Sidec AB.

About Sidec:

Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec AB offers collaborative research projects to the biopharmaceutical industry that reveal unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope.

http://www.sidec.com


'/>"/>
SOURCE Sidec AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amazing minaturized SIDECAR drives Webb telescopes signal
2. DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
3. Baxa Announces Colorado BioScience Association Sponsorship
4. Poniard Pharmaceuticals Announces Upcoming Conference Participation
5. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
6. Anesiva Announces Expansion of Zingo Agreement in Europe
7. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
8. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
9. BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center
10. Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands
11. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):